TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Authors:
- Ayana T. RuffinARAyana T. Ruffin
- Vasili ToliopoulosVTVasili Toliopoulos
- Aubrey S. SmithASAubrey S. Smith
- Soundharya KumaresanSKSoundharya Kumaresan
- Megan M. WyattMWMegan M. Wyatt
- Meredith SalzingerMSMeredith Salzinger
- Anna C. ColeACAnna C. Cole
- Megen C. WittlingMWMegen C. Wittling
- Rachel L. MasonRMRachel L. Mason
- James H. CarmoucheJCJames H. Carmouche
- Mahmoud A. AbdelbaryMAMahmoud A. Abdelbary
- Yuan LiuYLYuan Liu
Open Access
- 6 July 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (19) , 4840-4855
Abstract
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance: B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.Keywords
All Related Versions
Funding Information
- Cancer Research Institute (CRI5296)
- Burroughs Wellcome Fund (1271742)
- National Cancer Institute (R01CA300792)
- National Cancer Institute (R01CA287866)
- National Cancer Institute (R01CA275199)
This publication has 53 references indexed in Scilit:
- GP100 expression is variable in intensity in melanomaCancer Immunology, Immunotherapy, 2024
- The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunityCancer Cell, 2023
- B cell-rich niches support stem-like CD8+ T cells in cancer microenvironmentCancer Cell, 2023
- Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)Current Rheumatology Reports, 2021
- SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell ResolutionCell Metabolism, 2020
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell, 2019
- Adoptive cellular therapies: the current landscapeVirchows Archiv, 2018
- Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell, 2017
- Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient HumansCell Reports, 2016
- CD5 expression is regulated during human T‐cell activation by alternative polyadenylation, PTBP1, and miR‐204European Journal of Immunology, 2016